Neurol. praxi. 2020;21(1):31-34 | DOI: 10.36290/neu.2020.031
Long term efficacy of ocrelizumab on MRI parameters in multiple sclerosis patients
- Neurologická klinika FN Ostrava
Multiple sclerosis (MS) is a long term inflammatory and neurodegenerative disease with variable course. Ocrelizumab, a humanized monoclonal antibody that targets CD20 receptor on B-lymphocytes and leads to depletion of these cells, represents a new drug available for treatment of MS. The rate of brain atrophy progression, which significantly correlates with neurological disability, and possibility of its deceleration by treatment, is nowadays one of the most important aspects of MS patients´ management. Magnetic resonance imaging is a very important part of monitoring of MS treatment. This review describes a long term efficacy of ocrelizumab on magnetic resonance parameters.
Keywords: multiple sclerosis, ocrelizumab, brain atrophy, magnetic resonance imaging
Received: November 20, 2019; Revised: December 9, 2019; Accepted: December 9, 2019; Prepublished online: December 9, 2019; Published: March 30, 2020 Show citation
